Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Low Tristetraprolin Expression is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2018 Nov 12. pii: cebp.0667.2018. doi: 10.1158/1055-9965.EPI-18-0667. [Epub ahead of print]

PMID:
30420441
2.

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.

Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, Briganti A.

Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30837-6. doi: 10.1016/j.eururo.2018.10.042. [Epub ahead of print]

PMID:
30409676
3.

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.

Lyon TD, Frank I, Sharma V, Shah PH, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Cheville JC, Boorjian SA.

World J Urol. 2018 Nov 3. doi: 10.1007/s00345-018-2551-9. [Epub ahead of print]

PMID:
30392012
4.

Radiotherapy for newly diagnosed oligometastatic prostate cancer.

Boeri L, Sharma V, Karnes RJ.

Lancet. 2018 Oct 18. pii: S0140-6736(18)32598-4. doi: 10.1016/S0140-6736(18)32598-4. [Epub ahead of print] No abstract available.

5.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [Epub ahead of print]

PMID:
30321406
6.

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.

Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30659-6. doi: 10.1016/j.eururo.2018.09.009. [Epub ahead of print]

PMID:
30301694
7.

Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.

Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.

Eur Urol Focus. 2018 Mar;4(2):288-293. doi: 10.1016/j.euf.2015.12.004. Epub 2015 Dec 24.

PMID:
30205893
8.

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R.

World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.

PMID:
30171454
9.

Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort.

Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, Sprenkle PC, Kattan MW, Colicchia M, Neville TB.

Front Oncol. 2018 Aug 6;8:296. doi: 10.3389/fonc.2018.00296. eCollection 2018.

10.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
11.

Genomic diversity in low-risk disease: present and future.

Sharma V, Karnes RJ.

Nat Rev Urol. 2018 Oct;15(10):594-596. doi: 10.1038/s41585-018-0073-2. No abstract available.

PMID:
30097623
12.

Much ado about robotic versus open radical prostatectomy.

Sharma V, Karnes RJ.

Lancet Oncol. 2018 Aug;19(8):1003-1004. doi: 10.1016/S1470-2045(18)30417-0. Epub 2018 Jul 17. No abstract available.

PMID:
30017350
13.

Temporal trends in venous thromboembolism after radical cystectomy.

Lyon TD, Tollefson MK, Shah PH, Bews K, Frank I, Karnes RJ, Thompson RH, Habermann EB, Boorjian SA.

Urol Oncol. 2018 Aug;36(8):361.e15-361.e21. doi: 10.1016/j.urolonc.2018.05.015. Epub 2018 Jun 7.

PMID:
29885792
14.

Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.

Bhindi B, Karnes RJ.

Eur Urol. 2018 Oct;74(4):534-535. doi: 10.1016/j.eururo.2018.05.021. Epub 2018 Jun 14. No abstract available.

PMID:
29866462
15.

The Association of Aspirin Use with Survival Following Radical Cystectomy.

Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

J Urol. 2018 Nov;200(5):1014-1021. doi: 10.1016/j.juro.2018.05.119. Epub 2018 May 30.

PMID:
29857079
16.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

PMID:
29760221
17.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

18.

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P.

World J Urol. 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2.

PMID:
29721611
19.

Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.

Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC.

J Urol. 2018 Nov;200(5):1075-1081. doi: 10.1016/j.juro.2018.04.070. Epub 2018 Apr 27.

PMID:
29709664
20.

Examining the association between adiposity and biochemical recurrence after radical prostatectomy.

Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK.

Can Urol Assoc J. 2018 Jul;12(7):E331-E337. doi: 10.5489/cuaj.4923. Epub 2018 Mar 19.

21.

More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.

Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA.

Eur Urol. 2018 Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12.

PMID:
29544737
22.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
23.

Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.

EMBO Mol Med. 2018 Apr;10(4). pii: e8478. doi: 10.15252/emmm.201708478.

24.

Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA.

J Cancer Res Clin Oncol. 2018 May;144(5):883-891. doi: 10.1007/s00432-018-2615-7. Epub 2018 Mar 6.

PMID:
29511883
25.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

PMID:
29453313
26.

Is it time for a more 'proactive' approach to metastatic prostate cancer?

Soligo M, Sharma V, Karnes RJ.

BJU Int. 2018 Feb;121(2):167-168. doi: 10.1111/bju.14107. No abstract available.

PMID:
29359528
27.

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.

PMID:
29307681
28.

Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.

Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ.

Eur Urol Focus. 2018 Jan 3. pii: S2405-4569(17)30292-4. doi: 10.1016/j.euf.2017.12.005. [Epub ahead of print]

PMID:
29306730
29.

The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy.

Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK.

Clin Genitourin Cancer. 2018 Jun;16(3):e629-e636. doi: 10.1016/j.clgc.2017.11.003. Epub 2017 Dec 6.

PMID:
29289518
30.

A House Divided: The Irradiation Versus Prostatectomy Debate Continues.

Zaid HB, Karnes RJ.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):512-514. doi: 10.1016/j.ijrobp.2017.01.220. No abstract available.

PMID:
29280441
31.

Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse.

Zattoni F, Morlacco A, Nehra A, Frank I, Boorjian SA, Thapa P, Karnes RJ.

Int Braz J Urol. 2018 May-Jun;44(3):491-499. doi: 10.1590/S1677-5538.IBJU.2017.0376.

32.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

33.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
34.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
35.

Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Gearman DJ, Morlacco A, Cheville JC, Rangel LJ, Karnes RJ.

J Urol. 2018 May;199(5):1188-1195. doi: 10.1016/j.juro.2017.11.116. Epub 2017 Dec 7.

PMID:
29225057
36.

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.

Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ.

Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28.

PMID:
29195777
37.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
38.

PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.

Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W.

Clin Cancer Res. 2018 Feb 15;24(4):834-846. doi: 10.1158/1078-0432.CCR-17-2006. Epub 2017 Nov 22.

39.

Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.

Murphy SJ, Kosari F, Karnes RJ, Nasir A, Johnson SH, Gaitatzes AG, Smadbeck JB, Rangel LJ, Vasmatzis G, Cheville JC.

Cancer Res. 2017 Nov 15;77(22):6157-6167. doi: 10.1158/0008-5472.CAN-17-0529. Epub 2017 Nov 10.

PMID:
29127096
40.

Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series.

Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ.

Urology. 2018 Feb;112:29-32. doi: 10.1016/j.urology.2017.10.016. Epub 2017 Oct 25.

PMID:
29079212
41.

Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.

Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, Briganti A.

Eur Urol. 2018 Jun;73(6):890-896. doi: 10.1016/j.eururo.2017.09.027. Epub 2017 Oct 16.

PMID:
29042125
42.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.

Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14. Review.

PMID:
29037513
43.

Prostatectomy versus Observation for Early Prostate Cancer.

Sharma V, Karnes RJ.

N Engl J Med. 2017 Sep 28;377(13):1302. doi: 10.1056/NEJMc1710384. No abstract available.

PMID:
28953432
44.

Author Reply.

Bhindi B, Karnes RJ.

Urology. 2017 Nov;109:152. doi: 10.1016/j.urology.2017.06.056. Epub 2017 Sep 21. No abstract available.

PMID:
28943048
45.

LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.

Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH.

Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.

46.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
47.

Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.

Mason RJ, Frank I, Bhindi B, Tollefson MK, Thompson RH, Karnes RJ, Tarrell R, Thapa P, Boorjian SA.

World J Urol. 2017 Dec;35(12):1879-1884. doi: 10.1007/s00345-017-2087-4. Epub 2017 Sep 14.

PMID:
28913657
48.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
49.

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.

Oncotarget. 2017 Feb 7;8(31):50804-50813. doi: 10.18632/oncotarget.15133. eCollection 2017 Aug 1.

50.

Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.

Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, Frank I, Griebling TL, Tollefson MK, Thompson RH, Holzbeierlein JM, Karnes RJ, Boorjian SA.

Clin Genitourin Cancer. 2017 Aug 1. pii: S1558-7673(17)30208-2. doi: 10.1016/j.clgc.2017.07.011. [Epub ahead of print]

PMID:
28844793

Supplemental Content

Loading ...
Support Center